Article

Increased suicidality in mania complicated by alcoholism.

Psychiatry 04/2007; 4(4):34-9.
Source: PubMed

ABSTRACT Objective. This retrospective study was done to assess the impact of concurrent alcohol use on the illness presentation of patients hospitalized for mania.Design. Retrospective demographic and clinical data were systematically collected from the hospital records of 122 patients hospitalized for an index episode of mania between 1988 and 1995. Comorbid alcoholism was defined as alcohol abuse/dependence, based on DSM-IV criteria. Blind to alcohol use and treatment intervention, a retrospective clinical assessment of illness severity was made by the Clinical Global Impression (CGI) at the end point of hospital discharge. Demographic and clinical differences between the alcoholic and nonalcoholic manic subjects were analyzed by chi-square and independent t-tests. Survival analyses with hospital length of stay as the dependent variable were conducted on the two groups.Setting. Tertiary care university hospital.Participants. Patients with bipolar disorder hospitalized for mania.Measurements. Clinical Global Impression (CGI), clinical variables (suicidality, polysubstance abuse, hospital length of stay).Results. Alcoholic manic and nonalcoholic manic patients differed significantly in two categorical measures: suicidality on admission (36.7 vs. 18.5%) and current polysubstance abuse/dependence (46.6 vs. 7.6%). There was no significant difference in length of hospitalization between the two groups.Conclusions. The results of this study are consistent with previous studies that have found an association between alcoholism and increased suicidality and polysubstance abuse in bipolar disorder.

0 Followers
 · 
67 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bipolar disorder (BD) is more prevalent among people with substance use disorders (SUD) than the general population. SUD among recidivist driving under the influence (DUI) populations are extremely prevalent; not surprisingly, recent evidence suggests that rates of BD also are elevated among DUI offenders. Studies of BD patients with SUD have found high prevalence of other psychiatric disorders and relatively low rate of treatment engagement. This study examines both the prevalence of other mental disorders and treatment status among a cohort of DUI offenders with BD and SUD. A consecutively selected cohort (N=729) of repeat DUI offenders attending a two-week inpatient treatment program completed a standardized diagnostic interview (the Composite International Diagnostic Interview: CIDI). The CIDI generated DSM-IV diagnoses. This study yielded three main results for this repeat DUI offender sample: (1) BD is associated with significantly higher lifetime prevalence of alcohol, drug, and non-substance psychiatric disorders (e.g., PTSD); (2) approximately one quarter of BD participants have not discussed their mania with a professional; and (3) only half of the BD participants in this cohort have had mania treatment they consider effective and even fewer have had any treatment during the past twelve months. Participants were predominantly Caucasian males attending treatment as a sentencing option in a single Massachusetts DUI program. These findings suggest that clinicians in DUI treatment settings should consider both evaluating for BD and initiating therapy.
    Journal of Affective Disorders 08/2009; 121(3):253-7. DOI:10.1016/j.jad.2009.06.015 · 3.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Bipolar manic episodes often require hospital admission to ensure patient safety. The antipsychotic quetiapine is a common treatment for bipolar mania and is available in immediate release (IR) and extended release (XR) formulations; however, outcomes in patients receiving these different formulations have not been directly compared in an acute hospital setting.Methods We conducted a multinational, observational, retrospective cohort study to describe and compare hospital stay in patients admitted for an acute bipolar manic episode treated with quetiapine IR or XR from 1 October 2009¿1 October 2010. The primary outcome measure was comparison of length of stay (LOS) using zero-truncated negative binomial regression.ResultsIn total, 1230 patients were included (659 in the IR cohort; 571 in the XR cohort). The median LOS (interquartile range) was 18.0 days (12.0, 28.0) in the IR cohort and 20.0 days (12.0, 34.0) in the XR cohort, respectively. LOS was not significantly associated with quetiapine formulation irrespective of whether or not clinical characteristics were taken into account (p¿=¿0.820 and p¿=¿0.386, respectively). Overall, 84.2% and 84.4% of patients in the IR and XR cohorts, respectively, had not previously used quetiapine; of these patients, 78.7% and 68.9% received one total daily dose, and 14.4% and 23.9% received dose titration. Over half of patients received antipsychotic monotherapy (53.1% and 58.3% in the IR and XR cohorts, respectively) and most received a daily quetiapine dose ¿400 mg (64.9% and 71.8%, respectively, for quetiapine monotherapy and 59.9% and 80.3%, respectively, for combination treatment).As a secondary outcome, multivariate analysis was used to identify other factors that affect LOS. Factors associated with a longer hospital stay included public funding versus private, maximum number of new medications administered, did not receive lithium and did not receive anxiolytics, sedatives/hypnotics (all p¿<¿0.0001). Factors associated with a shorter hospital stay included presence of drug/alcohol abuse, living accompanied and having a psychiatric medical history (all p¿<¿0.05).ConclusionsLOS was not found to be associated with quetiapine formulation. However, most patients received only one total daily dose of quetiapine without dose titration, which was unexpected and contrary to current recommendations.Trial registrationTrial registration: NCT01239589.
    BMC Psychiatry 08/2014; 14(1):246. DOI:10.1186/s12888-014-0246-3 · 2.24 Impact Factor

Preview

Download
0 Downloads
Available from